Form 4: Galectin CEO Joel Lewis Exercises Options, Sells Shares

Galectin Therapeutics CEO Joel Lewis executed pre-planned transactions, exercising stock options and selling an equivalent number of shares for a profit.

Summary

• Joel Lewis, President and CEO of Galectin Therapeutics Inc., engaged in pre-planned transactions under a Rule 10b5-1 plan.
• On November 17, 2025, Lewis exercised options to acquire 15,680 shares of common stock at $2.39 per share and simultaneously sold 15,680 shares at a weighted average price of $6.0359.
• On November 18, 2025, Lewis exercised options to acquire 6,783 shares of common stock at $2.39 per share and simultaneously sold 6,783 shares at a weighted average price of $6.1511.
• The options exercised were fully vested on December 14, 2018, and are set to expire on December 14, 2027.
• Following these transactions, Lewis directly beneficially owns 832,592 shares of common stock.
• An additional 2,000 shares are held indirectly as custodian for a minor child, with beneficial ownership disclaimed by Lewis.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, the transactions were pre-planned under a Rule 10b5-1 plan, indicating a routine liquidity event rather than a reaction to adverse company news. The executive realized a significant profit on the option exercises, which is a positive for the individual.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 plan, indicating a planned liquidity event rather than a reaction to new, undisclosed information.
• The sales were executed at a significant profit, with shares sold at weighted average prices of $6.0359 and $6.1511 against an exercise price of $2.39.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by investors as it reduces the insider's direct equity stake.

Future Outlook

NA

Industry Context

These transactions represent routine insider activity for a public company executive, specifically the exercise of vested stock options and the subsequent sale of shares, often for diversification or liquidity purposes. The use of a Rule 10b5-1 plan indicates a pre-scheduled transaction, which is a common practice to avoid accusations of trading on material non-public information.

Related Party Transactions

• 2,000 shares are held indirectly by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act, though beneficial ownership is disclaimed.

Stakeholder Impact

• Shareholders may view the insider selling with slight caution, though the pre-planned nature mitigates concerns about trading on non-public information.
• The transactions provide liquidity for the executive, which is a common and expected part of executive compensation.

Next Steps

• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Key Dates

Recommendation

The Form 4 filing details routine, pre-planned insider transactions (option exercise and sale) by the CEO. These transactions do not provide new fundamental information about Galectin Therapeutics' operational performance or strategic direction. While the CEO realized a profit, the sales were executed under a Rule 10b5-1 plan, which suggests a planned liquidity event rather than a signal of negative future prospects. Therefore, based solely on this filing, there is no strong catalyst for a 'buy' or 'sell' recommendation; a 'hold' position is appropriate as investors await more substantive company updates.

Keywords

Galectin Therapeutics, GALT, Joel Lewis, Insider Trading, Form 4, Stock Options, Rule 10b5-1, CEO, Share Sale